Condition: Squamous Cell Carcinoma of Oropharynx · Squamous Cell Carcinoma of the Hypopharynx · Larynx Squamous Cell Carcinoma · Sponsor: University of Erlangen-Nürnberg Medical School
Analysis of tumor tissue (which is already available in pathology) and collection of saliva/stool and blood samples, which are obtained as part of a routine collection. These will be evaluated together with the patients' clinical data to identify possible predictors for treatment feasibility, survival, tumor control and potentially increased tumor immunogenicity by docetaxel.
This description comes directly from the study's public registry record.
Marlen Haderlein, MD · +49913185 · marlen.haderlein@uk-erlangen.de
Charlotte Schmitter, MD · +49913185 · charlotte.schmitter@uk-erlangen.de
Always discuss trial participation with your own doctor first.
| Universitätsklinikum Erlangen, Strahlenklinik | Erlangen, Bavaria, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06947668